Browsing Tag
bezuclastinib
2 posts
Why oncology investors are watching Cogent Biosciences, Inc.’s PEAK data closely
Why investors are closely watching Cogent Biosciences’ PEAK data and what bezuclastinib could mean for valuation, revenue growth, and oncology market sentiment.
Cogent Biosciences posts Q3 2025 results with $430m cash and pivotal trial momentum
Find out how Cogent Biosciences is using its $430 million cash runway and regulatory momentum to drive late-stage trials and pipeline expansion in 2025.